Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a single institution, randomized, placebo-controlled, double-blind phase IIB trial of
1) topical diclofenac and topical DFMO, or 2) placebo in participants with a history of non
melanoma skin cancer/ keratinocytic cancers.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)